Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing
暂无分享,去创建一个
Paul Bogdan | Mihai Udrescu | Lucreţia Udrescu | Alexandru Iovanovici | Alexandru Topîrceanu | Laura Sbârcea | Ludovic Kurunczi | P. Bogdan | L. Sbârcea | L. Kurunczi | L. Udrescu | M. Udrescu | A. Iovanovici | Alexandru Topîrceanu
[1] A. Graul,et al. The year's new drugs & biologics, 2013: Part I. , 2014, Drugs of today.
[2] Ruth Nussinov,et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.
[3] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[4] Mircea Vladutiu,et al. Network Fidelity: A Metric to Quantify the Similarity and Realism of Complex Networks , 2013, 2013 International Conference on Cloud and Green Computing.
[5] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[6] J. Zeldis,et al. Thalidomide as a novel therapeutic agent: new uses for an old product. , 2005, Drug discovery today.
[7] Kristen Fowler,et al. Hormone Replacement Therapy in Women with Epilepsy: A Randomized, Double‐Blind, Placebo‐Controlled Study , 2006, Epilepsia.
[8] M. Jacomy,et al. ForceAtlas2, a Continuous Graph Layout Algorithm for Handy Network Visualization Designed for the Gephi Software , 2014, PloS one.
[9] Daniel M. Green,et al. The Central and Peripheral Nervous Systems , 1989 .
[10] Louise Poissant. Part I , 1996, Leonardo.
[11] Jochen L. Leidner,et al. Computational drug repositioning based on side-effects mined from social media , 2016, PeerJ Comput. Sci..
[12] S. Sleigh,et al. Repurposing Strategies for Therapeutics , 2010, Pharmaceutical Medicine.
[13] C. Woolley,et al. Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model , 2016, eLife.
[14] Sarah Baxendale,et al. Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures , 2012, Disease Models & Mechanisms.
[15] Carole E Shardlow,et al. Utilizing Drug-Drug Interaction Prediction Tools during Drug Development: Enhanced Decision Making Based on Clinical Risk , 2011, Drug Metabolism and Disposition.
[16] Rong Wang,et al. Drug Repurposing Based on Drug–Drug Interaction , 2015, Chemical biology & drug design.
[17] Jen‐Shi Chen,et al. Cisplatin-induced acute hyponatremia leading to a seizure and coma: a case report. , 2011, Chang Gung medical journal.
[18] N. Bhattacharyya,et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. , 2012, Blood.
[19] E. Cruces,et al. The year's new drugs & biologics, 2014: Part I. , 2015, Drugs of today.
[20] Khader Shameer,et al. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. , 2015, Current topics in medicinal chemistry.
[21] Albert-László Barabási,et al. Endophenotype Network Models: Common Core of Complex Diseases , 2016, Scientific Reports.
[22] S. Theodoridou,et al. Laboratory Investigation of Platelet Function in Patients with Thalassaemia , 2014, Acta Haematologica.
[23] Thomas M Polasek,et al. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. , 2011, British journal of clinical pharmacology.
[24] Paul R Cohen,et al. DARPA's Big Mechanism program , 2015, Physical biology.
[25] Mathieu Bastian,et al. Gephi: An Open Source Software for Exploring and Manipulating Networks , 2009, ICWSM.
[26] R. Karl Rethemeyer,et al. Network analysis , 2011 .
[27] Mark E. J. Newman,et al. The Structure and Function of Complex Networks , 2003, SIAM Rev..
[28] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[29] Hongkang Mei,et al. Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..
[30] M. Valentovic,et al. Impact of Insulin or Tolbutamide Treatment on 14C-Arachidonic Acid Conversion to Prostacyclin and/or Thromboxane in Lungs, Aortas, and Platelets of Streptozotocin-induced Diabetic Rats , 1983, Diabetes.
[31] Pilar Gutiérrez Navarro,et al. Penicillin degradation catalysed by Zn(II) ions in methanol. , 2003, International journal of biological macromolecules.
[32] Susumu Goto,et al. Network-Based Analysis and Characterization of Adverse Drug-Drug Interactions , 2011, J. Chem. Inf. Model..
[33] Weida Tong,et al. In silico drug repositioning: what we need to know. , 2013, Drug discovery today.
[34] Kay-Tee Khaw,et al. Dietary Potassium and Stroke-Associated Mortality - A 12 Year Prospective Population Based Study , 1986 .
[35] Monica Milani,et al. Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.
[36] Bence Bolgár,et al. Drug repositioning for treatment of movement disorders: from serendipity to rational discovery strategies. , 2013, Current topics in medicinal chemistry.
[37] M E J Newman,et al. Community structure in social and biological networks , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] M. Dickson,et al. The cost of new drug discovery and development. , 2004, Discovery medicine.
[39] Liliane Mouawad,et al. vSDC: a method to improve early recognition in virtual screening when limited experimental resources are available , 2016, Journal of Cheminformatics.
[40] O Epstein,et al. Platelet aggregation and thromboxane A2 release in primary biliary cirrhosis and effect of D-penicillamine treatment. , 1988, Prostaglandins, leukotrienes, and essential fatty acids.
[41] Richard Svensson,et al. In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions , 2011, Pharmaceutical Research.
[42] Andreas Noack,et al. An Energy Model for Visual Graph Clustering , 2003, GD.
[43] A. Shaughnessy. Old drugs, new tricks , 2011, BMJ : British Medical Journal.
[44] King C. Lee,et al. Potentiation of the pressor response to stress by tolbutamide in dogs , 1993, Integrative physiological and behavioral science : the official journal of the Pavlovian Society.
[45] John Newsom-Davis,et al. A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis , 1998, Neurology.
[46] Zhiyong Lu,et al. A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..
[47] D. C. Henckel,et al. Case report. , 1995, Journal.
[48] G. Zlokarnik,et al. In silico prediction of drug safety: despite progress there is abundant room for improvement. , 2004, Drug discovery today. Technologies.
[49] E. Chautard,et al. Interaction networks: from protein functions to drug discovery. A review. , 2009, Pathologie-biologie.
[50] R P Carlson,et al. The antiinflammatory action of guanabenz is mediated through 5-lipoxygenase and cyclooxygenase inhibition. , 1987, European journal of pharmacology.
[51] L. Lewis,et al. Drug-drug interactions: is there an optimal way to study them? , 2010, British journal of clinical pharmacology.
[52] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[53] D. Holdstock. Past, present--and future? , 2005, Medicine, conflict, and survival.
[54] Tudor I. Oprea,et al. Impact of similarity threshold on the topology of molecular similarity networks and clustering outcomes , 2016, Journal of Cheminformatics.
[55] M. J. van den Bent,et al. Cisplatin-induced encephalopathy and seizures. , 2003, Anti-cancer drugs.
[56] Andreas Noack,et al. Modularity clustering is force-directed layout , 2008, Physical review. E, Statistical, nonlinear, and soft matter physics.
[57] Xue-Qing Chen,et al. Discovery pharmaceutics—Challenges and opportunities , 2006, The AAPS Journal.
[58] M. Udrescu,et al. Evaluation of patients diagnosed with essential arterial hypertension through network analysis , 2016, Irish Journal of Medical Science (1971 -).
[59] K Kawaguchi,et al. Tolbutamide effect on cultured human endothelial cells with special reference to platelet aggregation. , 1983, The Tohoku journal of experimental medicine.
[60] D. Dréau,et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. , 2004, Molecular cancer therapeutics.
[61] Edward M. Reingold,et al. Graph drawing by force‐directed placement , 1991, Softw. Pract. Exp..
[62] Guanrong Chen,et al. Complex networks: small-world, scale-free and beyond , 2003 .
[63] Christian Bauckhage,et al. Network growth and the spectral evolution model , 2010, CIKM.
[64] M Hirohashi,et al. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems. , 1991, Arzneimittel-Forschung.
[65] Mihai Udrescu,et al. Data Analysis for Patients with Sleep Apnea Syndrome: A Complex Network Approach , 2014, SOFA.